Call Us: 1.800.873.5297

By

FDA Requires New Labeling Change for Testosterone Drugs Regarding Increased Risk of Heart Attack and Stroke

defective-drugs-imgOn March 3, 2015, the Food and Drug Administration (FDA) issued a Safety Announcement cautioning that testosterone products are approved only for men who have low testosterone levels caused by certain medical conditions, rather than due to aging. The FDA also required manufacturers of testosterone drugs to clarify the approved uses of these medications and add information to their product labels regarding a possible increased risk of heart attacks and strokes for patients taking these testosterone boosting drugs. This Safety Announcement is an update to the FDA’s previous Safety Announcement issued on January 31, 2014 where the FDA announced that it was investigating a potential link between testosterone use and stroke, heart attack and death.

The FDA now cautions as follows: “The benefit and safety of these medications have not been established for the treatment of low testosterone levels due to aging, even if a man’s symptoms seem related to low testosterone. We are requiring that the manufacturers of all approved prescription testosterone products change their labeling to clarify the approved uses of these medications. We are also requiring these manufacturers to add information to the labeling about a possible increased risk of heart attacks and strokes in patients taking testosterone. Health care professionals should prescribe testosterone therapy only for men with low testosterone levels caused by certain medical conditions and confirmed by laboratory tests.”

An Advisory Committee Meeting was held on September 17, 2014 for the purpose of discussing the appropriate indicated population for testosterone replacement therapy and the potential for adverse cardiovascular outcomes associated with this use. The members of the Advisory Committee unanimously agreed that manufacturers of testosterone drugs should further study the potential cardiovascular health risks of testosterone products and who should take these drugs. Based on the available evidence from published studies and input from experts during the Advisory Committee Meeting, the FDA concluded that there is a possible increased cardiovascular risk associated with testosterone use. The FDA is not only requiring labeling changes to reflect the possible increased risk of heart attacks and strokes, but is also requiring manufacturers of these testosterone boosting drugs to conduct a well-designed clinical trial investigating whether an increased risk of heart attack or stroke exists among users of these products.

According to the most recent report from the Judicial Panel on Multidistrict Litigation (JPML), there are over 1,000 testosterone lawsuits currently pending against the drug manufacturers in the United States District Court for the Northern District of Illinois before The Honorable Judge Matthew F. Kennelly (In re: Testosterone Replacement Therapy Products Liability Litigation, MDL 2545). Schlichter, Bogard & Denton are leaders in the national Low-T Multidistrict Litigation. In early July, Judge Kennelly appointed Kristine Kraft of Schlichter, Bogard & Denton to the Plaintiffs’ Steering Committee, which will oversee and manage the growing number of cases pending against the Low-T manufacturers. If you or a loved one has suffered injuries after using testosterone products, please contact the attorneys at Schlichter, Bogard & Denton, LLP toll-free at 1-800-873-5297 for your confidential and free consultation.

 

The choice of a lawyer is an important decision and should not be based solely on advertisements. The cases discussed do not predict outcomes in future cases. Past results afford no guarantee of future results and every case is different and must be judged on its own merits.

000-017   000-080   000-089   000-104   000-105   000-106   070-461   100-101   100-105  , 100-105  , 101   101-400   102-400   1V0-601   1Y0-201   1Z0-051   1Z0-060   1Z0-061   1Z0-144   1z0-434   1Z0-803   1Z0-804   1z0-808   200-101   200-120   200-125  , 200-125  , 200-310   200-355   210-060   210-065   210-260   220-801   220-802   220-901   220-902   2V0-620   2V0-621   2V0-621D   300-070   300-075   300-101   300-115   300-135   3002   300-206   300-208   300-209   300-320   350-001   350-018   350-029   350-030   350-050   350-060   350-080   352-001   400-051   400-101   400-201   500-260   640-692   640-911   640-916   642-732   642-999   700-501   70-177   70-178   70-243   70-246   70-270   70-346   70-347   70-410   70-411   70-412   70-413   70-417   70-461   70-462   70-463   70-480   70-483   70-486   70-487   70-488   70-532   70-533   70-534   70-980   74-678   810-403   9A0-385   9L0-012   9L0-066   ADM-201   AWS-SYSOPS   C_TFIN52_66   c2010-652   c2010-657   CAP   CAS-002   CCA-500   CISM   CISSP   CRISC   EX200   EX300   HP0-S42   ICBB   ICGB   ITILFND   JK0-022   JN0-102   JN0-360   LX0-103   LX0-104   M70-101   MB2-704   MB2-707   MB5-705   MB6-703   N10-006   NS0-157   NSE4   OG0-091   OG0-093   PEGACPBA71V1   PMP   PR000041   SSCP   SY0-401   VCP550  

Legal Disclaimer & Privacy Policy
This web site is designed for general information only. The information presented should not be construed as legal advice and does not form the basis for an attorney/client relationship.

The choice of a lawyer is an important decision and should not be based solely on advertisements.
This web site is not intended to be advertising, and Schlichter Bogard & Denton LLP does not desire to represent anyone desiring representation based upon viewing this web site in a jurisdiction where this web site fails to comply with all laws and ethical rules of that jurisdiction. Materials on this web site may only be reproduced in their entirety (without modification) for the individual reader's personal and/or educational use and must include this notice.

We will not disclose, sell, or rent any of your identifiable personal information to any third party, unless approved by you, or required by law.